Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein Journal Article


Authors: Ohh, M.; Takagi, Y.; Aso, T.; Stebbins, C. E.; Pavletich, N. P.; Zbar, B.; Conaway, R. C.; Conaway, J. W.; Kaelin, W. G. Jr
Article Title: Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein
Abstract: The von Hippel-Lindau tumor suppressor protein (pVHL) negatively regulates hypoxia-inducible mRNAs such as the mRNA encoding vascular endothelial growth factor (VEGF). This activity has been linked to its ability to form multimeric complexes that contain elongin C, elongin B, and Cul2. To understand this process in greater detail, we performed a series of in vitro binding assays using pVHL, elongin B, and elongin C variants as well as synthetic peptide competitors derived from pVHL or elongin C. A subdomain of elongin C (residues 17-50) was necessary and sufficient for detectable binding to elongin B. In contrast, elongin B residues required for binding to elongin C were not confined to a discrete colinear domain. We found that the pVHL (residues 157-171) is necessary and sufficient for binding to elongin C in vitro and is frequently mutated in families with VHL disease. These mutations preferentially involve residues that directly bind to elongin C and/or alter the conformation of pVHL such that binding to elongin C is at least partially diminished. These results are consistent with the view that diminished binding of pVHL to the elongins plays a causal role in VHL disease.
Keywords: gene mutation; human cell; mutation; protein conformation; protein domain; proteins; protein protein interaction; cell line; protein binding; transcription, genetic; peptide; transcription factors; regulatory mechanism; amino acid sequence; molecular sequence data; messenger rna; tumor suppressor proteins; peptide fragments; tumor protein; models, molecular; cell hypoxia; von hippel lindau disease; protein structure; ubiquitin-protein ligases; ligases; hippel-lindau disease; von hippel-lindau tumor suppressor protein; humans; human; priority journal; article
Journal Title: Journal of Clinical Investigation
Volume: 104
Issue: 11
ISSN: 0021-9738
Publisher: American Society for Clinical Investigation  
Date Published: 1999-12-01
Start Page: 1583
End Page: 1591
Language: English
PUBMED: 10587522
PROVIDER: scopus
PMCID: PMC481054
DOI: 10.1172/JCI8161
DOI/URL:
Notes: Article -- Export Date: 16 August 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors